New targeted drug shows promise for Hard-to-Treat cancers

NCT ID NCT05161390

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new drug called LM-302 in 153 people with advanced solid tumors that have a specific protein called CLDN18.2. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals were to check safety, find the right dose, and see early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LM-302 (an antibody-drug conjugate targeting CLDN18.2)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific marker called CLDN18.2.

What could go wrong

This is an early-phase trial, so the drug may not work or could cause serious side effects. Results are preliminary and need confirmation in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China